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1. Introduction 
Trauma is a significant cause of mortality (10%) worldwide and is responsible for 15% of all 
disability-adjusted life years (DALYs) (Murray & Lopez, 1997). Seven of the top 30 
contributors to the global burden of disease are due to injury, including motor vehicle 
accidents, falls, war injuries, self-inflicted injuries, violence, drowning and burns. All of 
these injuries are seen in the trauma setting and places trauma workers at risk of exposure to 
blood and other body fluids. The relevance of HIV and trauma is increasing as the global 
prevalence of HIV continues to rise.  Sixty million have been infected with HIV since the 
beginning of the epidemic and 25 million have died of HIV-related causes (UNAIDS, 2009). 
Of those newly infected, 40% were young people - the group most likely to be involved in 
trauma. 
2. Universal precaution 
In general, the risk of transmission of any infectious disease may be minimised in the 
trauma setting by implementing universal precautions. The World Health Organization 
(WHO) has developed universal precaution guidelines which are summarised below 
(WHO, 2007). 
 Hand wash after any direct contact with patients 
 Safe collection and disposal of sharps 
 Gloves for contact with body fluids, non intact skin and mucous membranes 
 Wearing a mask, eye protection and a gown if blood or other body fluids might splash 
 Covering cuts and abrasions 
 Cleaning of spills of blood and other bodily fluids 
 Safe system for hospital waste management and disposal 
In addition, the WHO advocates Hepatitis B virus (HBV) vaccination of healthcare workers, 
development of post exposure protocols for those at risk of contact with infected body 
fluids, adequate provision of personal protective equipment (PPE) with appropriate means 
of disposal, and monitoring of staff training and use of PPE. 
Historically, trauma workers have generally had poor compliance with universal precaution 
guidelines. In a Jamaican study, where health care workers were interviewed to determine 
the reason for not adhering to universal precautions, numerous reason were provided 
including: (1) increase in workload made adherence difficult, (2) a perceived reduction in 
dexterity when wearing gloves, (3) insufficient supply of PPE and (4) lack of penalties for 
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not adhering to universal precautions (Vaz et al., 2010). Other studies in the United States 
have reached similar conclusions and also highlighted that trauma workers have a poor 
knowledge of infection risk (Kelen et al. 1990; Kim et al., 1999) 
3. Post-exposure prophylaxis 
Post-exposure prophylaxis (PEP) is the collection of measures taken after exposure to a 
pathogen in order to prevent or reduce the risk of transmission. In the case of HIV, such 
measures should include, but are not limited to, first-aid, appropriate HIV testing, 
counselling, anti-retroviral (ARV) chemotherapy, and follow-up. The risk of occupational 
exposure to healthcare workers in the trauma setting depends on the relative prevalence of 
HIV in the trauma population and the level of exposure. The use of PEP in patients 
attending the trauma service should also be considered in cases of sexual assault and other 
forms of acute non-occupational exposure. It is strongly recommended that all trauma 
services have well established PEP protocols, sufficient resources and necessary training for 
effective implementation. 
The only direct evidence supporting the prophylactic use of ARV chemotherapy 
(zidovudine) for healthcare associated HIV exposure comes from a single case-control study 
involving patients from the United States, United Kingdom, France and Italy (Cardo et al., 
1997). Healthcare workers were 81% less likely to seroconvert if they received zidovudine 
after a needlestick injury and the risk of seroconversion was linked to the volume of blood 
transmitted and the HIV blood titre level.  Indirect evidence supporting the prophylactic use 
of ARVs include reduced rates of vertical transmission in HIV positive mothers who 
received zidovudine and the success of ARVs in raising CD4+ counts, reducing viral titres, 
and  decreasing  morbidity and mortality in HIV positive patients (Connor et al., 1996). 
3.1 Occupational exposure 
The risk of HIV transmission through needlestick injury is 0.3%. The risk of transmission from 
contact of contaminated fluids with mucous membranes or damaged skin is approximately 
0.09%. However, the risk of occupational exposure in trauma may be higher than in other 
hospital settings. This is because the HIV status of patients is usually unknown, the prevalence 
of HIV in the trauma population is generally greater than the community, the mechanism of 
injury is often violent and may increase the level of exposure, and the emergent nature of 
trauma increases the situational stress and may lead to riskier practice.   
PEP is only indicated in cases where there is a risk of transmission (Table 1) and contra-
indicated in cases where there is no appreciable benefit (Table 2).  For occupational 
exposure, this includes contact between body fluids at risk of HIV contamination and non-
intact skin or mucous membranes. Indirect evidence from animal studies suggest that 
initiation of PEP after 72 hours following exposure is not effective at reducing rates of 
seroconversion. PEP should therefore not be offered in such cases and strategies should exist 
to offer PEP as soon as possible after exposure (Martin et al., 1993).  Starter packs are well-
suited to the emergency department as they offer quick access to ARVs, may result in less 
wasted medication if PEP is not continued, requires the patient to attend follow-up to obtain 
additional ARVs ensuring appropriate testing and counselling, and can easily be placed in 
small or under-serviced departments. Theoretical risk of HIV resistance may develop if 
starter packs are inappropriately used or ARV courses are not routinely completed.   
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Exposure between body fluids suspected of, or confirmed to be, HIV positive and: 
 Non-intact skin (needlestick, sharp injury, skin abrasion) 
 Mucous membranes (oral cavity, nasal cavity, eyes) 
 Sexual contact in cases where a condom was not used, broke or fell off during 
intercourse 
 Oral sex with ejaculation1 
Table 1. Indications for PEP2 
 
 Patient is already HIV positive from previous exposure 
 Exposure has been chronic3 
 Exposure through intact skin 
 Sexual contact with condom use that remains intact 
 Exposure to non-infectious body fluids such as saliva, faeces, urine, and sweat 
 Exposure to HIV negative body fluids 
 Greater than 72 hours have elapsed since exposure 
Table 2. Contraindications to PEP2 
3.2 Exposure as a result of sexual assault 
The risk of non-occupational exposure depends on the nature of contact with contaminated 
fluids. In cases of sexual assault, the method of assault, the condition of genital or oral 
mucosa, the circumcision status, and the level of HIV virulence all play a role. Risk is 
increased in cases of rape, where there is decreased lubrication and may be associate with 
violent penetration.  Children, especially small children, are also at an increased risk for 
anatomical reasons.  Generalised risk from a single sexual contact depends on the method of 
exposure. Published estimates of HIV transmission for receptive anal intercourse are 1-30%, 
insertive anal intercourse 0.1-10%, receptive vaginal intercourse 0.1-10%, and insertive 
vaginal intercourse 0.1-1% (Boily et al., 2009).  Case studies have also reported transmission 
from oral sex with ejaculation (Lifson et al., 1990; Rozenbaum et al., 1988).  
PEP should be offered to all victims of sexual assault attending the trauma service where the 
act occurred within 72 hours.  In many cases, particularly with children, the assault may be 
on a background of chronic abuse, in which case PEP is not indicated. However, special care 
should be taken to distinguish between cases of chronic abuse and cases of acute-on-chronic 
abuse where a different perpetrator is responsible for the most recent assault. In such cases, 
PEP should be offered.  
                                                 
1 The risk for oral transmission is considered very low but PEP may be offered in cases where the 
exposure is in association with significat oral disease such as ulceration or dysplasia 
2 Adapted from: WHO. Post-exposure prophylaxis to prevent HIV infection: Joint WHO/ILO guidelines 
on post-exposure prophylaxis (PEP) to prevent HIV infection. HIV/AIDS Programme: Strengthening health 
services to fight HIV/AIDS. 2007 
3 Chronic exposure should be distinguished from episodic exposure where PEP may still be effective. 
This distinction may be challenging. 
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3.3 Other types of exposure 
Routine PEP after community-acquired needlestick injury is controversial and 
administration should be based on risk assessment. At risk populations include children, 
security workers and cleaners (Celenza et al., 2011). Children from communities with low 
prevalence of HIV may not warrant PEP (Makwana & Riordan, 2005). Care should also be 
taken to ensure exposure was within 72 hours as presentation to the emergency department 
may be delayed (Johnston & O'Conor, 2005).  
The risk associated with needle-sharing is approximately 0.67%.  PEP for needle-sharing 
may also be offered if presented within 72 hours and where exposure is likely to be acute 
rather than chronic. 
3.4 PEP regimens 
When indicated, the ARV regimen used depends on various factors including national 
policy, institutional policy, level of resources, toxicity and side-effects, daily pill burden, 
drug contra-indications and compliance. Although a single drug regimen using zidovudine 
has shown to be effective, multi-drug regimens are now more commonly used in order to 
cover drug-resistant HIV clones. The use of two drugs must be weighed against cost, 
toxicity and availability. A third drug may be considered in cases where the background 
prevalence of ARV resistance is greater than 15%. 
Two drug regimens include fixed-dose dual nucleoside reverse transcriptase inhibitor 
(NRTI) therapy with combination zidovudine-lamivudine or combination tenofovir-
emtricitabine. A protease inhibitor (PI), usually in combination with ritonavir, which 
increases PI plasma levels, are usually added if a third drug is necessary. Combination 
ritonavir-lopinavir, -atazanavir, -darunavir have all been used. All PEP regimens are given 
for 28 days post exposure. 
3.5 Testing, follow-up and counselling 
Testing of the source patient, in cases where HIV status is unknown, should include rapid-
ELISA testing for HIV as well as testing for HBV (surface antigen - HBsAg) and Hepatitis C 
virus (HCV). In cases where HIV or HCV infection has occurred within the last 2-4 weeks, 
HIV or HCV RNA PCR may be indicated. 
Testing of the exposed patient should be carried out as soon as possible to establish a 
baseline for follow-up testing. Tests should include a rapid-ELISA for HIV, HBV immunity 
status (anti-HB antibodies), HBsAg and HCV antibodies. Baseline full blood count, liver 
enzymes and creatinine should also be obtained to monitor for PEP side-effects and sequelae 
from hepatitis infection. Screening for other sexually transmitted infections may be 
warranted in cases of sexual assault or in patients with high risk behaviour. 
At the minimum, follow-up testing at 6 months should be performed to document HIV 
negative status. Seroconversion after 6 months in those receiving PEP has been reported but 
is extremely rare (Ippolito et al., 1999). More intensive follow-up can include HIV and HCV 
antibody testing at 4-6 weeks, 3 months, and 6 months.  Relevant additional testing should 
be offered in patients who become symptomatic or experience drug toxicity. 
Post-exposure counselling should form an integral part of the PEP protocol. Services should 
be available to address HIV testing, follow-up testing, ARV treatment, legal issues and 
compensation claims should they arise. In the event that HIV is contracted, services should 
be available to address relevant needs. Counselling to address special needs of certain 
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population sub-groups such as children and victims of sexual assault should also be made 
available. 
4. Management and outcome of HIV positive patients in trauma 
The function of a trauma unit is to stabilise and treat life threatening injuries. It has been 
shown that HIV alone is not responsible for mortality in trauma but rather the patient’s 
ability to mount an immune response (Allard & Meintjies, 2005). It is also unethical to not 
treat life-threatening conditions based on a patient’s HIV status (Smit 2010). In fact, a 
number of studies have suggested that HIV positive patients have the same mortality rate as 
non-infected patients, especially if they are in the early stages of the disease (Smit, 2010). 
With regard to surgical outcomes, early views were often pessimistic. It was felt that HIV 
positive patients were prone to poor wound healing, high post-operative complication rates, 
a prolonged post-operative period and higher mortality rates. This helped trigger a number 
of studies investigating the morbidity and complication rates among HIV positive patients 
both in general and orthopaedic surgery. 
Many such studies have produced conflicting results. Duane et al conducted a retrospective 
study comparing outcomes of HIV positive and HIV negative patients over a 5-year period 
in the trauma unit. They found no difference in infection rates or overall complications 
based on CD4+ count alone (Duane et al., 2008). Conversely, Karpelowsky et al showed that 
in children who were HIV positive or exposed to HIV had increased rates of poor wound 
healing and breakdown of reconstruction sites (Karpelowsky et al., 2009). Other post-
operative complications cited in the study were likely due to non-HIV related factors. For 
example, a large proportion of the children studied underwent emergency surgery, which is 
known to have higher rates of post-operative complications since the children tend to be 
sicker at presentation. This is true for both HIV positive and HIV negative patients. It was 
also found that up to 79% of children included in the study were undernourished and 36% 
had other co-morbid diseases including major respiratory and nutritional problems prior to 
undergoing surgery. 
Stawicki et al found that HIV positive patients had both longer length of hospital stay as 
well as longer length of stay in ICU (Stawicki et al., 2005). They noted however, that HIV 
positive patients had more pulmonary, infectious and renal complications than the control 
group and suggested that the mortality of HIV positive patients was likely linked to these 
co-morbid processes. They also found that HIV positive patients needed greater numbers of 
surgical procedures but failed to state what the indication for these procedures were.  
Studies by Morrison et al and Horberg et al found similar findings to Stawicki et al, stating 
that HIV positive patients had higher post-operative complication rates, especially 
respiratory complications (Horberg et al., 2006; Morrison et al., 2010). 
Studies comparing complication rates in orthopaedic surgeries have been small and only 
tentative conclusions can be drawn. It has been shown that HIV positive patients with an 
open fracture (depending on the contamination of the wound) have a higher rate of 
infection, especially deep infection. There is also a higher rate of late sepsis with procedures 
that need internal instrumentation, but sepsis may have been avoided with improved 
medical management including prophylactic antibiotic use before invasive procedures as 
well as early evaluation and treatment of possible infections (Luck Jr, 1994; Van Aardt, 
2010). 
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The overwhelming conclusion in all these studies however, has been that there is not 
enough evidence to properly evaluate the relationship between HIV and outcomes after 
trauma. There is a significant deficiency in research in this particular area and often 
available data is extrapolated from studies determining the effect of HIV on patients 
undergoing surgical procedures, either emergency or elective. Unfortunately, researchers 
face an ethical challenge when testing for HIV in the trauma setting and it is unlikely that 
sufficiently powered studies with adequate controls are possible in the current medical 
climate.  
5. Drug interference between ARVs and commonly used trauma drugs 
Currently available ARVs inhibit the reverse transcriptase and protease enzymes of the 
human immunodeficiency virus. These drugs are associated with many side-effects and 
close monitoring is mandatory. It is also important in the trauma setting to recognise a 
patient’s HIV status and the possible concurrent use of ARVs since administration of drugs 
with potential for interaction may to lead to adverse outcomes. 
First-line treatment of HIV involves the use of 2 NRTIs and a non-nucleoside transcriptase 
inhibitor (NNRTI). Protease inhibitors are used as second line therapies (Town, 2003). 
Common side effects of NRTIs include lactic acidosis, hypersensitivity reactions, 
pancreatitis, peripheral neuropathy and hepatic dysfunction (as most are metabolised in the 
liver). NNRTIs are known inducers or inhibitors of other drugs due to their effect on the 
hepatic cytochrome systems, and hypersensitivity reactions are common. Protease inhibitors 
undergo hepatic cytochrome P450 (CYP450) metabolism and many in this class are potent 
hepatic inhibitors. 
Table 3 outlines the drug interactions between NNRTIs or protease inhibitors and other 
drugs that are dependent on CYP450 metabolism. Many potential interactions of other 
commonly used drugs remain unknown and have not been included. It is important to 
take a drug history to ensure that potential side effects can be avoided or closely 
monitored. In cases where drugs must be administratered, dose adjustment may limit 
side-effects. 
 
 Drugs ARV interaction Clinical Effects Management 
A Aminophylline Protease inhibitors 
Decreased 
theophylline 
effects 
Monitor and adjust 
theophylline levels as 
indicated 
 Amiodarone 
NNRTI 
Protease inhibitors 
Increased 
amiodarone effects 
(hypotension, 
bradycardia, 
cardiac 
arrhythmias 
Monitor and adjust 
amiodarone as 
indicated, with 
reduction of 
amiodarone dose as 
needed 
Should not be co-
administered with 
PIs 
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 Drugs ARV interaction Clinical Effects Management 
B Bactrim Lamivudine 
Increased 
Lamivudine 
levels? 
 Unknown at present 
but no dose 
adjustment necessary 
for either drug 
 Beta- Blockers Protease inhibitors  
Increased effects of 
Beta-blockers 
Use with caution 
D Diazepam 
Zidovudine, 
Protease inhibitors, 
Efavirenz  
Increased 
diazepam levels 
(increased 
sedation, respire-
atory depression) 
Do not co-administer 
Alternative agents: 
Lorazepam, 
oxazepam, 
temazepam  
 Digoxin Protease inhibitor 
Increased digoxin 
levels 
Monitor digoxin 
levels closely 
 Dilitiazem Efavirenz 
Decreased 
dilitiazem effects 
Titrate dilitiazem to 
clinical effect 
F Fentanyl 
NNRTI 
Protease inhibitors 
Increased effects of 
Fentanyl  
Close monitoring 
necessary 
 Flagyl Protease Inhibitors 
Disulfiram-like 
reaction 
Do not co-administer 
 Furosemide 
NNRTI 
Protease inhibitors 
Lamivudine 
Increased effects of 
ARVS? 
Use with caution  
H Haloperidol 
NNRTIs 
PIs 
Increased 
haloperidol effects 
Monitor and adjust 
dosage as indicated 
 
I Ipecac All 
Decreased effects 
of ARVs if recently 
ingested due to 
induced vomiting 
Avoid concurrent use 
K Ketamine NNRTIs 
Reduced effects of 
ketamine 
Monitor and adjust 
dose as necessary 
L Lidocaine Protease Inhibitors 
Increased lidocaine 
levels 
Monitor and adjust 
lidocaine dose 
M 
Methyl-
prednisone 
NNRTIs 
Protease Inhibitors 
Possibly increased 
methylprednisone 
effects 
Monitor while using 
 Midazolam 
NNRTI 
Protease inhibitors 
 
Increased 
midazolam effects 
(increased 
sedation, 
confusion, respire-
atory depression) 
Single dose IV 
midazolam may be 
used; chronic 
midazolam 
administration 
should be avoided  
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 Drugs ARV interaction Clinical Effects Management 
 Morphine Protease inhibitors 
Increased 
morphine levels 
(increased sedation 
and respir-atory 
depression) 
Monitor closely when 
using together 
N Nitroglycerine Protease inhibitors 
Possible increase in 
effects of nitro-
glycerine 
Not known- but 
monitor for 
hypotension 
P Phenergan 
NNRTIs 
Protease inhibitors 
Unknown  
Monitor closely in 
used concurrently for 
side effects 
 Phenobarbitol 
NNRTIs, 
Protease inhibitors 
Decreased NNRTI 
and PI levels 
Avoid combination if 
possible 
 Phenytoin 
NNRTIs 
Protease inhibitors 
Decreased NNRTI 
and PI levels 
Avoid combination if 
possible 
 Prednisone 
NNRTIs  
Protease Inhibitors 
Possibly increased 
prednisone effects 
Close monitoring 
S Succinylcholine 
NNRTI 
Protease inhibitors 
Possible 
prolongation of 
effects of 
succinylcholine 
 
Use with caution 
Table 3. Commonly used drugs in the trauma unit and possible complications (McNicholl 
2011;  University of Cape Town 2003; University of Liverpool 2010) 
6. Conclusion 
It is likely that trauma units will see an increasing number of HIV positive patients in the 
years to come. In an area still lacking adequate research, trauma workers need to be diligent 
to approach the HIV positive patient in the context of their presentation. They must also stay 
vigilant to protect themselves against transmission. It is hoped that as HIV prevention and 
treatment improve, HIV patients will no longer represent a unique cohort and their 
management,  and most importantly, their outcomes, will be as good as those without HIV. 
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